BioPharmSignal logoBioPharmSignal

Biotech News

ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026

ADMA Biologics (ADMA)ADMA BiologicsEarnings

Conference Call Scheduled for November 4, 2026, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and

Related news

ADMAADMA Biologics2026-11-04 21:05 EST

ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update

ADMAADMA Biologics2026-07-29 11:00 EST

ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026

CHRSCoherus BioSciences, Inc.2026-10-26 13:30 EST

Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026

RXRXRecursion2026-11-02 21:30 EST

Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair

MDXGMiMedx2026-10-28 20:03 EST

MIMEDX Announces Third Quarter 2026 Operating & Financial Results

MDXGMiMedx2026-10-14 20:01 EST

MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026

RXRXRecursion2026-07-29 12:30 EST

Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th

CHRSCoherus BioSciences, Inc.2026-07-22 17:36 EST

Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026

PHARPharming Group2026-07-16 06:00 EST

Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30

PHARPharming Group2026-04-23 06:00 EST

Pharming Group to report first quarter 2026 financial results and provide business update on May 7

View all latest news

ADMA Biologics

Plasma-Derived Biologics ADMA Biologics is a vertically integrated U.S. manufacturer and marketer of plasma-derived immunoglobulin therapies for immunodeficient patients and people at risk of infection. ASCENIV ASCENIV is an intravenous immunoglobulin enriched with antibodies against respiratory syncytial virus. It is positioned for...

Recent company news

ADMAADMA Biologics2026-11-04 21:05 EST

ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update

ADMAADMA Biologics2026-10-28 11:00 EST

ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026

ADMAADMA Biologics2026-10-15 11:00 EST

ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process

ADMAADMA Biologics2026-08-05 20:05 EST

ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update

ADMAADMA Biologics2026-07-29 11:00 EST

ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026

Stock data

Close
13.21 USD
Market cap
1.76B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States